Participated · Series A · Jul 2026

Buildforce operates a two-sided platform composed of a mobile application for individual electricians to find and perform work and a web application for electrical contractors to find and manage electricians. The company focuses exclusively on the electrical trade within commercial and industrial construction and has logged over 2,000,000 electrician hours across more than 2,000 projects. Founded in 2019 and based in Houston and Austin, Texas, Buildforce positions itself as a modern marketplace with workflow integrations beyond simple job posting. With the new Series A financing, the company plans to expand nationally and further develop its technology. Management emphasizes a mission to improve careers in the construction trades while scaling to meet growing demand driven by data center construction, infrastructure investment, and the energy transition.

Participated · Series A · Jul 2026

Ognomy offers an AI-enabled virtual sleep care platform aimed at treating sleep apnea. The company plans to use its recently raised capital to expand access to its virtual platform, accelerate product development, and scale operations across the U.S. Ognomy secured $20 million in a Series A financing that included investments from UB Business and Entrepreneur Partnerships' Buffalo Innovation Seed Fund. The financing announcement frames the investment as part of regional efforts to support high-growth startups and the local innovation ecosystem. No revenue, user metrics, or founding year were provided in the article. The company is headquartered in Buffalo.

Led · Series A · Nov 2025

Vend Park offers a single platform that combines agentic AI with an in-house operations team to replace the traditional two-vendor parking model for commercial real estate owners. Its software automates daily parking management, unifies access, billing, and reporting, and delivers a seamless driver experience while boosting property net operating income by about 30 % and trimming operating costs by 30–50 %. Over the last 24 months, the company says it has achieved 35× growth, scaling from 3 to 15 U.S. cities and winning customers such as Nuveen, Jamestown, Federal Realty, and Harwood International. The system is deployed across office towers, mixed-use sites, healthcare facilities, hotels, campuses, event venues, and airports. Vend positions parking as “digital infrastructure” that can unlock trapped revenue and real-time data for owners. The new capital will fuel national market expansion, accelerate its AI product roadmap, and support hiring across sales, engineering, and customer success teams. Headquartered in Boston, the firm markets itself as turning parking into a strategic lever for property value creation.

Participated · Series B · Sep 2024

BlackCloak is an Orlando, FL–based company that specializes in digital executive protection and personal cybersecurity for corporate executives, high-net-worth individuals, and family offices. Its BlackCloak Concierge Cybersecurity & Privacy™ platform helps shield clients from threats such as deepfakes, advanced social engineering, cyber-extortion, doxxing, and physical threats. The company is used by Fortune 500 and Fortune 50 companies, the world’s largest financial institutions, prominent public officials, and talent management firms in the entertainment industry. Led by CEO and founder Dr. Chris Pierson, BlackCloak markets itself as a trusted solution for high-profile clients across industries. The company raised $17M in a Series B to support product development and protection services; the round brought total funding to $30M. BlackCloak says it will use the proceeds to enhance its personal cybersecurity platform for executives, high-net-worth individuals, and family offices. BlackCloak provides a Concierge Cybersecurity & Privacy™ platform that protects corporate executives and high‑profile individuals from cybersecurity, privacy, financial, and reputational risks. The holistic solution includes mobile and desktop apps as well as concierge support. Led by CEO and founder Dr. Chris Pierson, the company published 2020 research showing 40% of executives were already compromised, 70% had exposed passwords on the deep/dark web, and 87% had no security installed on personal devices. BlackCloak is used by Fortune 500 companies across industries. The company intends to use the funds to expand its proprietary technology offering in cybersecurity and privacy, deepen relationships with members, and grow its team and sales operations. BlackCloak is a US creator of a cybersecurity platform that provides Concierge Cybersecurity services to high-net-worth individuals, high-profile persons, and corporate executives. The platform protects clients in their personal lives to mitigate hacking, financial, and reputational risks. The company is led by Dr. Chris Pierson, Founder and CEO. BlackCloak raised $1.9M in funding from DataTribe. It intends to use the funds to strengthen its concierge cybersecurity platform and expand its presence within key sectors where cybercrime losses and intellectual theft are on the rise. As part of the investment, John Funge, Chief Product Officer at DataTribe, will join BlackCloak’s board of directors.

Participated · Series D · Sep 2024

CSA Medical develops the RejuvenAir System, a liquid nitrogen spray cryotherapy device intended to treat chronic bronchitis in COPD patients. The company says the technology targets overproduction of mucus and damaged cilia by destroying damaged cells without creating scar tissue, enabling regrowth of healthy airway cells. Led by CEO Wendelin Maners, CSA Medical is preparing a comprehensive commercialization strategy and plans a U.S. launch. The company intends to use the new funds to finance that U.S. launch despite an anticipated premarket approval (PMA) from the U.S. Food and Drug Administration. Board additions tied to the financing include Dr. Luc Marengere of TVM and Dr. Deng Mao of Yonjin Ventures. The company positions RejuvenAir as a therapeutic platform for an under-served patient population with chronic bronchitis. CSA Medical develops and manufactures proprietary interventional spray cryotherapy platforms—truFreeze and Rejuvenair—using liquid nitrogen spray delivered by a software‑driven device with specialty catheters to flash‑freeze and destroy unwanted tissue. The company manufactures and distributes the truFreeze system in the U.S., where it is being used in over 100 hospitals and universities to treat conditions such as Barrett’s esophagus, esophageal cancer, and airway obstructions. Its RejuvenAir Metered Cryospray system is designed to ablate mucus‑producing goblet cells while preserving the extracellular matrix and is currently under clinical investigation. Rejuvenair is not yet commercially available as it advances toward clinical and regulatory milestones. Led by Executive Chairman Vincent P. Owens, the company intends to expand commercial adoption of truFreeze in the GI market while progressing Rejuvenair through clinical development. CSA Medical develops the truFreeze spray cryotherapy system that uses super-cold liquid nitrogen delivered via catheter to ablate unwanted tissue inside the body. The company is based in Baltimore. In 2013 CSA raised $16 million in a Series C led by Ascension Ventures, which it planned to use to expand its R&D footprint in Lexington, Mass. CSA is currently pursuing a debt offering targeted at $3.9 million and has raised a little more than $2.9 million to date. The debt offering includes options and warrants and has attracted some 30 unnamed investors so far. Publicly listed backers on the company's website include Ascension, SV Life Sciences, Intersouth Partners, First Analysis, Rose Park Advisors and Blue Heron Capital. CSA Medical develops and manufactures a proprietary interventional spray cryotherapy platform comprised of a device and specialty catheters that deliver extremely cold (-196°C) liquid nitrogen to flash-freeze and destroy unwanted tissue inside the body. The truFreeze System has been used by physicians to ablate tissue in the esophagus and airway and is designed to destroy frozen cells while preserving underlying connective tissue to allow healthy cells to regenerate. The company completed a $16 million Series C financing to support growth and product development. Proceeds will be used to develop new applications, immediately double the sales force, and introduce new products in 2014. The Series C was led by Ascension Ventures and was oversubscribed with all existing investors participating. Tara Butler, MD of Ascension Ventures will join CSA Medical's board, indicating active investor engagement. CSA Medical develops and manufactures the Spray Cryotherapy System, a therapeutic interventional platform that delivers -196°C liquid nitrogen via a device and specialty catheters to freeze and destroy unwanted tissue inside the body. The system is currently used via endoscopic application to treat esophageal disease. Its product is being used at more than 80 top-ranked cancer centers and academic teaching hospitals across the United States. Proceeds from the recent financing will fund post-market clinical studies and ongoing development to support new indications and expanded utilization. Management intends to support the launch of a new platform and pursue new clinical applications, including therapeutic treatments for the airway. The company completed a $20.5 million Series B to support growth and expansion of its patented and currently marketed system.